Menu
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Buy Currently
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Sample Portfolio
Sample Portfolio Analysis
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Account Requirements
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
Municipal Bond Presentation
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Normally Buy
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF® Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Latest News about RHHVF
Recent news which mentions RHHVF
< Previous
1
2
3
4
5
Next >
Roche Decides To Terminate Cancer Treatment Pact With Blueprint Medicines
February 23, 2023
Tickers
BPMC
RHHBF
RHHBY
RHHVF
Tags
Benzinga
BPMC
RHHVF
From
Benzinga
New Data Shows Roche's Vabysmo Improves Vision, Retinal Fluid In Retinal Disorder
February 10, 2023
Tickers
REGN
RHHBF
RHHBY
RHHVF
Tags
General
RHHBF
Eurasia
From
Benzinga
Roche Touts Positive Crovalimab Data From Late-Stage Study In Rare Blood Condition
February 07, 2023
Tickers
RHHBF
RHHBY
RHHVF
Tags
Biotech
General
RHHBF
From
Benzinga
Roche Flags Lower 2023 Sales On Declining Demand For COVID-19 Treatment, Diagnostics
February 02, 2023
Tickers
RHHBF
RHHBY
RHHVF
Tags
Earnings
Health Care
Briefs
From
Benzinga
Genentech's Tecentriq Plus Avastin Combo Cuts Risk of Cancer Returning In Early-Stage Liver Cancer
January 19, 2023
Tickers
RHHBF
RHHBY
RHHVF
Tags
RHHVF
Benzinga
Briefs
From
Benzinga
Europe Approves Xofluza, Roche's Revolutionary Influenza Antiviral with New Mechanism
January 12, 2023
Tickers
RHHBF
RHHBY
RHHVF
Tags
Briefs
Health Care
Benzinga
From
Benzinga
Roche's Investigational Lymphoma Candidate Goes Under FDA Priority Review
January 06, 2023
Tickers
RHHBF
RHHBY
RHHVF
Tags
FDA
Biotech
RHHBF
From
Benzinga
Roche's Follicular Lymphoma Therapy Scores FDA Approval
December 23, 2022
Tickers
BIIB
RHHBF
RHHBY
RHHVF
Tags
Briefs
Health Care
RHHVF
From
Benzinga
FDA Approves Roche's Tocilizumab As First Monoclonal Antibody For COVID-19 Treatment
December 22, 2022
Tickers
LLY
RHHBF
RHHBY
RHHVF
Tags
Briefs
Health Care
Benzinga
From
Benzinga
Roche Presents New Data Demonstrating Potential Benefit Of Two Lymphoma Candidates
December 12, 2022
Tickers
RHHBF
RHHBY
RHHVF
Tags
Health Care
Briefs
RHHVF
From
Benzinga
After 16 Years, Roche's Pharma Division Head Decides To Step Down
December 12, 2022
Tickers
NSRGY
RHHBF
RHHBY
RHHVF
Tags
Briefs
Health Care
Benzinga
From
Benzinga
Replimune Shares Surge After Early Data From Pretreated Melanoma Patients
December 07, 2022
Tickers
BMY
REPL
RHHBF
RHHBY
Tags
RHHVF
Benzinga
Small Cap
From
Benzinga
Don't Use These 5 Non-Cost Effective COVID Treatments Including Antivirals From Merck and Gilead, Britain's NICE Says
November 16, 2022
Tickers
AZN
AZNCF
GILD
GSK
Tags
General
RHHBF
RHHBY
From
Benzinga
FDA Gives Emergency Use Nod To Roche's Monkeypox Test
November 16, 2022
Tickers
RHHBF
RHHBY
RHHVF
Tags
Market News
RHHBY
Large Cap
From
Benzinga
Successful Alzheimer's Data Would Have Placed Roche At Two-Year Competitive Advantage
November 15, 2022
Tickers
BIIB
ESALY
LLY
RHHBF
Tags
Biotech
BIIB
Analyst Color
From
Benzinga
Roche Inks Second Drug Discovery Deal With Jnana Therapeutics
November 15, 2022
Tickers
RHHBF
RHHBY
RHHVF
Tags
RHHVF
Benzinga
Briefs
From
Benzinga
Roche's Alzheimer's Flop Trial Removes One Competitor, But Reimbursement Debate Lingers
November 14, 2022
Tickers
BIIB
ESALF
ESALY
MOR
Tags
General
RHHBF
Market News
From
Benzinga
Roche's Another Alzheimer's Hopeful Flops In Phase 3 Program, Second Trial Setback Within Months
November 14, 2022
Tickers
MOR
RHHBF
RHHBY
RHHVF
Tags
Biotech
MOR
General
From
Benzinga
Roche Posts Lower Quarterly Sales As Demand For COVID Products Slide
October 18, 2022
Tickers
RHHBF
RHHBY
RHHVF
Tags
RHHVF
Benzinga
Earnings
From
Benzinga
Roche's Muscular Atrophy Treatment Improves Motor Function In Pretreated Patients
October 12, 2022
Tickers
BIIB
NVS
PTCT
RHHBF
Tags
RHHVF
Benzinga
PTCT
From
Benzinga
Roche To Introduce Next-Generation Portfolio Of COVID-19 Rapid Tests
October 12, 2022
Tickers
RHHBF
RHHBY
RHHVF
Tags
RHHBF
General
Large Cap
From
Benzinga
EXCLUSIVE: Lineage Cell Establishes New R&D Facility In US, Expands Israel-Based Facility
October 03, 2022
Tickers
LCTX
RHHBF
RHHBY
RHHVF
Tags
Benzinga
RHHVF
Health Care
From
Benzinga
FDA To Review Smaller Number Of Emergency Use Requests For COVID-19 Tests
September 27, 2022
Tickers
A
ABT
BDX
BRKR
Tags
BRKR
TMO
PKI
From
Benzinga
COVID-19 Complacency Pushes Identification Of New Variants To Back Seat, WHO Warns
September 23, 2022
Tickers
A
ABT
BDX
BRKR
Tags
RHHBY
COVID/19 Coronavirus
Market News
From
Benzinga
Europe Approves First Bispecific Antibody From Roche For Two Eye Disorders
September 19, 2022
Tickers
REGN
RHHBF
RHHBY
RHHVF
Tags
General
RHHBF
RHHBY
From
Benzinga
WHO Recommends Against Roche, GSK's COVID-19 Therapies Rendering Them Obsolete
September 16, 2022
Tickers
GSK
REGN
RHHBF
RHHBY
Tags
Biotech
REGN
General
From
Benzinga
No More Free COVID-19 At-Home Tests, Federal Government Says
August 29, 2022
Tickers
A
ABT
BDX
BRKR
Tags
CEMI
Top Stories
News
From
Benzinga
Citi Is Bullish On This Large Pharma Stock On Upcoming Data Readout From Diabetes Candidate
August 25, 2022
Tickers
ESALF
ESALY
LLY
RHHBF
Tags
General
RHHBF
Price Target
From
Benzinga
China-Based Jemincare Inks Prostate Cancer Drug Pact With Roche's Genentech
August 18, 2022
Tickers
RHHBF
RHHBY
RHHVF
Tags
News
Contracts
Large Cap
From
Benzinga
Roche's Polivy Combo Regime Under FDA Review For Type Of Blood Cancer
August 16, 2022
Tickers
RHHBF
RHHBY
RHHVF
SGEN
Tags
Briefs
Health Care
RHHVF
From
Benzinga
< Previous
1
2
3
4
5
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.